Last update Dec. 29, 2022
Very Low Risk
Pamidronate is an aminobisphosphonate that, like other bisphosphonates, inhibits bone resorption. It is used to treat Paget's disease, severe hypercalcemia, and osteolytic bone lesions associated with malignancy. It is administered by slow intravenous infusion every day or every 3 to 4 weeks depending on the disease.
Pamidronate is excreted in breast milk in undetectable concentration. (Siminoski 2000)
Most bisphosphonates are acidic compounds that achieve low plasma concentration. Both features make it unlikely excretion into the milk in clinically significant amount. Intestinal absorption of bisphosphonates is very low even during fasting and is considered negligible in the presence of milk due to formation with the calcium of non absorbable compounds.
No problems have been observed in infants of mothers treated with pamidronate (Mastaglia 2010, Shenker 2010, Chan 2006, Siminoski 2000),except some cases of mild and asymptomatic hypocalcemia in infants whose mothers had been already treated before and / or during pregnancy (Hassen 2010, Munns 2004), so some authors suggest regular monitoring of serum calcium. (Green 2014, Stathopoulos 2011)
Most osteoporosis treatments are compatible with breastfeeding.
We do not have alternatives for Pamidronate Disodium since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM